Therapy News and Research

RSS

Predicting breast cancer drug response by 20/20 GeneSystems’ PredicTOR test

20/20 GeneSystems, Inc. will present results this week at the Breast Cancer Symposium 2012 (San Francisco) of a 45 patient study showing the usefulness of its PredicTOR test in predicting response of breast tumors to the drug Herceptin.

13 Sep 2012

Brigham Young University scientists discover cellular cause of birth defects

The cellular cause of birth defects like cleft palates, missing teeth and problems with fingers and toes has been a tricky puzzle for scientists. Now Professor Emily Bates and her biochemistry students at Brigham Young University have placed an important piece of the developmental puzzle. They studied an ion channel that regulates the electrical charge of a cell. In a new study published by the journal Development, they show that blocking this channel disrupts the work of a protein that is supposed to carry marching orders to the nucleus.

13 Sep 2012

Case Western Reserve researcher discovers new antivirulence drugs against MRSA and strep

Menachem Shoham, PhD, associate professor of biochemistry at Case Western Reserve University School of Medicine, has discovered novel antivirulence drugs that, without killing the bacteria, render Methicillin Resistant Staphylococcus Aureus (MRSA) and Streptococcus pyogenes, commonly referred to as strep, harmless by preventing the production of toxins that cause disease.

13 Sep 2012

Changes in physical characteristics of regulatory T cell can predict MDS progression risk

Researchers at Moffitt Cancer Center and colleagues have discovered that changes in the physical characteristics of the effector memory regulatory T cell can predict the progression risk of myelodysplastic syndromes (MDS) to acute myeloid leukemia. The finding could improve prognostication for patients with MDS and better inform therapeutic decision making.

13 Sep 2012

AtriCure receives FDA approval for surgical treatment of atrial fibrillation

AtriCure, Inc., the leader in surgical ablation for the treatment of Atrial Fibrillation, has announced FDA approval of the ABLATE Post Approval Study (PAS).

13 Sep 2012

Viewpoints: Questions Obama, Romney not likely to answer in debates; Disturbing news on tests for ovarian cancer

New evidence that women are more likely to be harmed than helped by screening tests for ovarian cancer is disturbing. The tests do nothing to prevent healthy women from dying from the usually fatal disease. Yet they often lead doctors to perform needless surgeries that cause serious complications in many patients.

13 Sep 2012

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has approved AUBAGIO (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

13 Sep 2012

Positive data from Tetraphase Pharmaceuticals’ eravacycline Phase 2 trial on cIAI

Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, presented new, positive Phase 2 clinical data on its lead drug candidate, eravacycline (TP-434), on September 11, 2012, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

13 Sep 2012

Combination chemotherapy confirmed viable for penile cancer

A combination of cisplatin and 5-fluorouracil is an effective and well-tolerated regimen for patients with squamous cell carcinoma of the penis, show study findings.

12 Sep 2012

Acupuncture therapy remains a prickly matter

Acupuncture may actually be effective for treating some types of chronic pain, a systematic review in the Archives of Internal Medicine shows.

12 Sep 2012

Transcept completes enrollment in TO-2061 Phase 2 trial for obsessive compulsive disorder

Transcept Pharmaceuticals, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial evaluating TO-2061 added as adjunctive therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to first-line treatment with an approved OCD medication.

12 Sep 2012

Gene therapy regimen can safely restore immune systems to children with Bubble Boy disease

UCLA stem cell researchers have found that a gene therapy regimen can safely restore immune systems to children with so-called "Bubble Boy" disease, a life threatening condition that if left untreated can be fatal within one to two years.

12 Sep 2012

Diet could avert toxic effects of quinine in patients with malaria

Scientists at The University of Nottingham say adverse side-effects caused by the anti-parasitic drug quinine in the treatment of malaria could be controlled by what we eat.

12 Sep 2012

APS conference to explore potential mechanisms behind health benefits of exercise

The effects of physical inactivity are, literally, hazardous to your health. Although the detrimental effects of being inactive are generally thought to be associated with childhood obesity and Type 2 diabetes, they have a significant impact on other illnesses. Physical inactivity contributed at least 25 percent to the prevalence of hip fractures, osteoporosis, coronary heart disease, and colon cancer according to recent data released by the U.S. Department of Health and Human Services.

12 Sep 2012

New model reveals how immune system functions under conditions of neutropenia

Cancer chemotherapy can be a life-saver, but it is fraught with severe side effects, among them an increased risk of infection. Until now, the major criterion for assessing this risk has been the blood cell count: if the number of white blood cells falls below a critical threshold, the risk of infection is thought to be high.

12 Sep 2012

iPad app revolutionising therapy for autistic children

Australian researchers have harnessed tablet technology to develop an iPad app that is set to revolutionise the way parents around the world provide in-home therapy for their autistic children.

12 Sep 2012

KaloBios commences KB003 Phase 2 trial in severe asthma

KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered monoclonal antibody, in subjects with severe asthma uncontrolled by corticosteroids.

12 Sep 2012

Book provides holistic view of post-traumatic stress disorder

Close to 5.2 million adults experience post-traumatic stress disorder (PTSD) every year. And it can affect anyone — from war veterans and abuse victims to persons directly or indirectly traumatized by violence, natural disaster or other catastrophes.

12 Sep 2012

Berkeley lab researchers link possible new oncogene with resistance to cancer drugs

A gene that may possibly belong to an entire new family of oncogenes has been linked by researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) to the resistance of breast cancer to a well-regarded and widely used cancer therapy.

12 Sep 2012

ApoB no better than current lipid markers in CVD risk prediction

Assessment of apolipoprotein B levels does not seem to improve cardiovascular disease risk prediction over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol, report researchers.

11 Sep 2012

Therapy News and Research

Predicting breast cancer drug response by 20/20 GeneSystems’ PredicTOR test

Brigham Young University scientists discover cellular cause of birth defects

Case Western Reserve researcher discovers new antivirulence drugs against MRSA and strep

Changes in physical characteristics of regulatory T cell can predict MDS progression risk

AtriCure receives FDA approval for surgical treatment of atrial fibrillation

Viewpoints: Questions Obama, Romney not likely to answer in debates; Disturbing news on tests for ovarian cancer

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Positive data from Tetraphase Pharmaceuticals’ eravacycline Phase 2 trial on cIAI

Combination chemotherapy confirmed viable for penile cancer

Acupuncture therapy remains a prickly matter

Transcept completes enrollment in TO-2061 Phase 2 trial for obsessive compulsive disorder

Gene therapy regimen can safely restore immune systems to children with Bubble Boy disease

Diet could avert toxic effects of quinine in patients with malaria

APS conference to explore potential mechanisms behind health benefits of exercise

New model reveals how immune system functions under conditions of neutropenia

iPad app revolutionising therapy for autistic children

KaloBios commences KB003 Phase 2 trial in severe asthma

Book provides holistic view of post-traumatic stress disorder

Berkeley lab researchers link possible new oncogene with resistance to cancer drugs

ApoB no better than current lipid markers in CVD risk prediction

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News